Author's response to reviews

Title: GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer

Authors:

Kristi D Lynn (kristi.lynn@utsouthwestern.edu)
D. Gomika Udugamasooriya (Gomika.Udugama@UTSouthwestern.edu)
Christina L Roland (CRolan@parknet.pmh.org)
Diego H Castrillon (Diego.Castrillon@UTSouthwestern.edu)
Thomas J Kodadek (kodadek@scripps.edu)
Rolf A Brekken (rolf.brekken@utsouthwestern.edu)

Version: 4 Date: 28 July 2010

Author's response to reviews: see over
July 28, 2010

Dr. Melissa Norton

Editor-in-Chief
BMC Cancer

Dear Dr. Norton:

My colleagues and I are pleased to submit the revised version of our manuscript entitled “GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer”. We are grateful to the reviewer’s as well as the editors of BMC Cancer for their facilitation in the acceptance of our manuscript. We have now addressed and remedied all of the issues listed below and are pleased to submit our final version.

1. Title: please ensure that the title is identical in the manuscript and the submission system. Currently they do not match.
Response: we have changed the title to so that the manuscript and submission system match

2. Affiliations: Each affiliation should be written in full, in the following format: Department, Institute, (Street), City, (Postal code), Country. This may mean repeating institutional addresses if the authors are from different departments within an institution.
Response: We have added full affiliations for each author.

3. Abstract: please ensure that the Abstract is present in the manuscript and matches exactly what is in the submission system. Currently they do not match.
Response: Thank you for the notification of this error we have corrected it.

4. Highlighting/tracking: Please remove all highlighting and tracking from the manuscript.
Response: all highlighting has been removed.

5. Title page: Please remove the running head and keywords from the title page.
Response: keywords and running title have been removed from the title page

6. Grant support: Please move the statement of funding to the Acknowledgements section and remove it from the title page.

Response: we have moved the grant support to the appropriate section as indicated.

7. Please remove the header from the manuscript.

Response: done

8. Email address: please include email addresses for all the authors on the title page, using the following format:
   AB: abcd@institution.ac.uk
   EF: efgh@generic.co.uk
   IJ: IJKL@corporation.com

Response: we have added email contact information for each author on the title page

9. Figures: The image file should not include the title (e.g. Figure 1... etc.) or figure number. The legend and title should be part of the manuscript file after the reference list. The figures are numbered automatically in the order in which they are uploaded.

Response: We have modified the figures as requested.

10. Figures: It is important for the final layout of the manuscript that the figures are cropped as closely as possible to minimise white space around the image. Our online figure guide contains full details for preparing files for submission and can be viewed here: http://www.biomedcentral.com/info/ifora/figures.

Response: We have modified the figures as requested.

11. Figures: Please ensure all mention of figures is consistent (it should be Figure or Fig but not a mixture of both).

Response: we have amended the text appropriately.

12. Typography: Please take this opportunity to check your manuscript for any typographical errors and to make any final corrections or revisions. This is the final proofing stage for your manuscript, and you will not be able to make any changes after acceptance.
Response: we have gone through the manuscript carefully and have addressed any typographical errors.

Thank you again for the opportunity to publish our work in BMC Cancer.

Sincerely,

Rolf A. Brekken, PhD
Associate Professor of Surgery and Pharmacology
Hamon Center for Therapeutic Oncology Research
UT-Southwestern Medical Center
6000 Harry Hines Blvd, NB8.222
Dallas, TX  75390-8593
Tel: 214 648 5151
Fax: 214 648 4940
rolf.brekken@utsouthwestern.edu